Competitive Generic Therapy Designations Growing Despite Lack Of Guidance
US FDA developing document describing program operations, but that has not stopped sponsors from requesting and receiving the breakthrough-like designation.
You may also be interested in...
Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.
Amid confusion about multiple priority and expedited pathways for US generic drug applications, industry asks which are a true advantage.
Energy and Commerce subcommittee unanimously advances reauthorization legislation with four added amendments, including one that would allow for certain generic sponsors to meet early and often with FDA to speed development.